Lantheus Holdings, Inc. LNTH
100.61 USD -0.09 (-0.09%)
At closeNov 6, 2026, 4:00 PM EST
100.61 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
100.40 Day range 101.02
50.16 52-week range 111.86
- YTD
- +51.18%
- 1 year
- +87.39%
News
benzinga.com Lantheus Holdings Q3 Adj. EPS $1.68 Beats $1.24 Estimate, Sales $389.913M Beat $359.757M Estimate Lantheus Holdings (NASDAQ:LNTH) reported quarterly earnings of $1.68 per share which beat the analyst consensus estimate of $1.24 by 35.48 percent. This is a 32.28 percent increase over earnings of…
globenewswire.com Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals Final rule maintains separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu™ Transitional Pass-Through status through September 30, 2029; permanent HCPCS code A9613 now…
globenewswire.com Lantheus Reports Third Quarter 2026 Financial Results Worldwide revenue of $389.9 million in the third quarter of 2026 GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025 Adjusted fully diluted earnings per…
globenewswire.com Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer's Disease Annual Meeting BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight…
benzinga.com This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded ACGL, ASTS, PS, LNTH and ADBE, cutting ratings and price targets; ASTS target fell to $54 and Adobe’s to $267.
benzinga.com Mizuho Downgrades Lantheus Holdings to Neutral, Lowers Price Target to $109 Mizuho analyst Anthony Petrone downgrades Lantheus Holdings (NASDAQ:LNTH) from Outperform to Neutral and lowers the price target from $115 to $109.
benzinga.com Lantheus Receives Transitional Pass-Through Payment Status For PYLARIFY TruVu Injection From Centers For Medicare & Medicaid Services, Effective Oct. 1 Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver…
benzinga.com Lantheus Holdings Announces First Patient Dosed In SPARROW NCT07831824, Phase 2/3 Registrational Trial Evaluating LNTH-2401 Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver…
benzinga.com FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics Lantheus receives FDA approval for PET imaging agent used to evaluate adults for Alzheimer's disease by identifying tau pathology.- benzinga.com Lantheus Holdings Announces FDA Approval Of TAUKLARIFY, Radiodiagnostic Agent Indicated For PET Of Brain In Adults For Alzheimer’s Disease Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver…
- benzinga.com Lantheus Holdings Q2 Adj. EPS $1.55 Beats $1.30 Estimate, Sales $388.200M Beat $362.416M Estimate Lantheus Holdings (NASDAQ:LNTH) reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.30 by 19.23 percent. This is a 1.27 percent decrease over earnings of…
- benzinga.com Truist Securities Downgrades Lantheus Holdings to Hold, Lowers Price Target to $102.5 Truist Securities analyst Richard Newitter downgrades Lantheus Holdings (NASDAQ:LNTH) from Buy to Hold and lowers the price target from $125 to $102.5.
benzinga.com TD Cowen Downgrades Lantheus Holdings to Hold, Lowers Price Target to $102.5 TD Cowen analyst Tara Bancroft downgrades Lantheus Holdings (NASDAQ:LNTH) from Buy to Hold and lowers the price target from $110 to $102.5.
benzinga.com Analyst Calls Curium's $8 Billion Lantheus Buyout An 'Excellent Outcome' For Shareholders CapVest-backed Curium agrees to acquire Lantheus for up to $8B, expanding its global footprint in nuclear medicine.
benzinga.com Under the Radar: 3 Boring Small Caps That Could Return 10x Investors spend an enormous amount of time searching for the next stock that can rise 10 times in value. They study disruptive technologies, enormous addressable markets, charismatic founders, and…- benzinga.com Mizuho Maintains Outperform on Lantheus Holdings, Lowers Price Target to $115 Mizuho analyst Anthony Petrone maintains Lantheus Holdings (NASDAQ:LNTH) with a Outperform and lowers the price target from $120 to $115.
benzinga.com Truist Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $125 Truist Securities analyst Richard Newitter maintains Lantheus Holdings (NASDAQ:LNTH) with a Buy and raises the price target from $115 to $125.- benzinga.com Mizuho Maintains Market Outperform on Lantheus Holdings, Raises Price Target to $120 Mizuho analyst Anthony Petrone maintains Lantheus Holdings (NASDAQ:LNTH) with a Market Outperform and raises the price target from $115 to $120.
- benzinga.com B. Riley Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $129 B. Riley Securities analyst Justin Walsh maintains Lantheus Holdings (NASDAQ:LNTH) with a Buy and raises the price target from $97 to $129.
benzinga.com FDA Manufacturing Issues Delay Lantheus' Tumor Imaging Kit Lantheus receives FDA Complete Response Letter for LNTH-2501. William Blair pushes Octevy sales outlook back by one year.
benzinga.com Citizens Reiterates Market Outperform on Lantheus Holdings, Maintains $115 Price Target Citizens analyst David Turkaly reiterates Lantheus Holdings (NASDAQ:LNTH) with a Market Outperform and maintains $115 price target.
benzinga.com Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutics, Universe Pharmaceuticals for earnings and news.- benzinga.com Lantheus Holdings Receives FDA Complete Response Letter For LNTH-2501 Due To Manufacturing Facility Issues; No Safety Or Efficacy Concerns Identified Lantheus Holdings, Inc. ("Lantheus" or "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better
- benzinga.com Mizuho Maintains Outperform on Lantheus Holdings, Raises Price Target to $115 Mizuho analyst Anthony Petrone maintains Lantheus Holdings (NASDAQ:LNTH) with a Outperform and raises the price target from $100 to $115.
benzinga.com 'Lantheus Weighs Potential $7 Billion Sale Following Offer From Curium' - Bloomberg News https://www.bloomberg.com/news/articles/2026-05-22/lantheus-is-said-to-weigh-sale-following-offer-from-curium- benzinga.com Truist Securities Reiterates Buy on Lantheus Holdings, Raises Price Target to $115 Truist Securities analyst Richard Newitter reiterates Lantheus Holdings (NASDAQ:LNTH) with a Buy and raises the price target from $98 to $115.
benzinga.com These Analysts Raise Their Forecasts On Lantheus After Upbeat Q1 Results Lantheus Holdings Inc (NASDAQ:LNTH) reported upbeat Q1 earnings, reaffirmed guidance, and received price target hikes from analysts.- benzinga.com Citizens Maintains Market Outperform on Lantheus Holdings, Raises Price Target to $115 Citizens analyst David Turkaly maintains Lantheus Holdings (NASDAQ:LNTH) with a Market Outperform and raises the price target from $85 to $115.
benzinga.com Airbnb To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday Wall Street analysts changed outlook on top names. Includes upgrades/downgrades. Check analyst ratings page for details on MCD, NKE, ABNB, LNTH, XYZ, ASTH, RNG, CELH.- benzinga.com Mizuho Maintains Outperform on Lantheus Holdings, Raises Price Target to $100 Mizuho analyst Anthony Petrone maintains Lantheus Holdings (NASDAQ:LNTH) with a Outperform and raises the price target from $95 to $100.
- benzinga.com Lantheus Holdings Affirms FY2026 Adj EPS Guidance of $5.00-$5.25 vs $5.17 Est; Affirms FY2026 Sales Guidance of $1.400B-$1.450B vs $1.450B Est Lantheus Holdings (NASDAQ:LNTH) affirms FY2026 Adj EPS guidance from $5.00-$5.25 to $5.00-$5.25 vs $5.17 analyst estimate. Affirms FY2026 sales outlook from $1.400 billion-$1.450 billion to $1.400…
- benzinga.com Lantheus Holdings Q1 Adj. EPS $1.46 Beats $1.24 Estimate, Sales $377.330M Beat $353.942M Estimate Lantheus Holdings (NASDAQ:LNTH) reported quarterly earnings of $1.46 per share which beat the analyst consensus estimate of $1.24 by 17.74 percent. This is a 4.58 percent decrease over earnings of…
benzinga.com Korn Ferry, Hewlett Packard Enterprise And 3 Stocks To Watch Heading Into Monday U.S. stock futures up, Korn Ferry, ZIM, Lantheus, HPE, and Caseys General Stores in focus for earnings. Check out premarket coverage.
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com This Union Pacific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com Nasdaq Surges 1%; Uber Sales Top Estimates - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com US Stocks Edge Higher; McDonald's Posts Upbeat Earnings - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For May 7, 2025
benzinga.com Root And ZoomInfo Are Among Top 8 Mid-Cap Gainers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio? Top mid-cap stock gainers in past week: Root, Bridge Investment Group, Huron Consulting, Medical Properties Trust, ZoomInfo Technologies, Lantheus Holdings, Alignment Healthcare, VSE. Analysts raise…
benzinga.com Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday 
benzinga.com Earnings Scheduled For February 26, 2025 - benzinga.com Radiopharm Theranostics Executed A Subscription Agreement For A Private Placement Of Ordinary Shares To Lantheus Holdings Inc., Raising $5M Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per share, representing a premium of 150% to the last closing price of A$0.024Lantheus…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Russell 2000 Index Notches Strongest Week Of Year, Hits 31-Month Highs: Outlook Is 'Clouded By Fed's Concerns Over Labor Market,' Analyst Warns The Russell 2000 index of small caps recorded its best weekly performance since October 2023, surging over 6%, driven by lower-than-expected June inflation data and potential interest rate cuts.
- benzinga.com Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session